Cargando…

RETRACTED ARTICLE: SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion

Detalles Bibliográficos
Autores principales:	Wang, Xinling, Xu, Wei, Hu, Gaowei, Xia, Shuai, Sun, Zhiping, Liu, Zezhong, Xie, Youhua, Zhang, Rong, Jiang, Shibo, Lu, Lu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136698/ https://www.ncbi.nlm.nih.gov/pubmed/32265513 http://dx.doi.org/10.1038/s41423-020-0424-9

Ejemplares similares

Retraction Note to: SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion
por: Wang, Xinling, et al.
Publicado: (2020)

The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin
por: Xia, Shuai, et al.
Publicado: (2020)

Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein
por: Xia, Shuai, et al.
Publicado: (2020)

High-throughput screening of mutations affecting SARS-CoV-2 spike functions
por: Xia, Shuai, et al.
Publicado: (2023)

Potent MERS-CoV Fusion Inhibitory Peptides Identified from HR2 Domain in Spike Protein of Bat Coronavirus HKU4
por: Xia, Shuai, et al.
Publicado: (2019)

Inefficiency of Sera from Mice Treated with Pseudotyped SARS-CoV to Neutralize 2019-nCoV Infection
por: Liu, Zezhong, et al.
Publicado: (2020)

Pan-coronavirus fusion inhibitors as the hope for today and tomorrow
por: Wang, Xinling, et al.
Publicado: (2021)

RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response
por: Liu, Zezhong, et al.
Publicado: (2020)

An engineered recombinant protein containing three structural domains in SARS-CoV-2 S2 protein has potential to act as a pan-human coronavirus entry inhibitor or vaccine antigen
por: Wang, Xinling, et al.
Publicado: (2023)

Peptide-Based Membrane Fusion Inhibitors Targeting HCoV-229E Spike Protein HR1 and HR2 Domains
por: Xia, Shuai, et al.
Publicado: (2018)

The putative mechanism of lymphopenia in COVID-19 patients
por: Wang, Xinling, et al.
Publicado: (2022)

Pyroptosis of syncytia formed by fusion of SARS-CoV-2 spike and ACE2-expressing cells
por: Ma, Huabin, et al.
Publicado: (2021)

Griffithsin with A Broad-Spectrum Antiviral Activity by Binding Glycans in Viral Glycoprotein Exhibits Strong Synergistic Effect in Combination with A Pan-Coronavirus Fusion Inhibitor Targeting SARS-CoV-2 Spike S2 Subunit
por: Cai, Yanxing, et al.
Publicado: (2020)

Structure-based evidence for the enhanced transmissibility of the dominant SARS-CoV-2 B.1.1.7 variant (Alpha)
por: Xia, Shuai, et al.
Publicado: (2021)

Survival of SARS-COV-2 under liquid medium, dry filter paper and acidic conditions
por: Sun, Zhiping, et al.
Publicado: (2020)

Broad-Spectrum Coronavirus Fusion Inhibitors to Combat COVID-19 and Other Emerging Coronavirus Diseases
por: Wang, Xinling, et al.
Publicado: (2020)

Engineered trimeric ACE2 binds viral spike protein and locks it in “Three-up” conformation to potently inhibit SARS-CoV-2 infection
por: Guo, Liang, et al.
Publicado: (2020)

A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases
por: Zhou, Jie, et al.
Publicado: (2022)

Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion
por: Xia, Shuai, et al.
Publicado: (2020)

RETRACTED ARTICLE: Regardless of inequities in care, terminal anorexia nervosa exists: a response to Sharpe et al.
por: Yager, Joel, et al.
Publicado: (2023)

Observations on article on healthcare workers & SARS-CoV-2 infection
por: Kulkarni, A.P.
Publicado: (2020)

Application of “B+1” heterologous boosting strategy for preventing infection of SARS-CoV-2 variants with resistance to broad-spectrum coronavirus vaccines
por: Liu, Zezhong, et al.
Publicado: (2023)

Lymphocyte integrins mediate entry and dysregulation of T cells by SARS-CoV-2
por: Huang, Mengwen, et al.
Publicado: (2023)

A novel cyclic γ-AApeptide-based long-acting pan-coronavirus fusion inhibitor with potential oral bioavailability by targeting two sites in spike protein
por: Xue, Songyi, et al.
Publicado: (2022)

Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein
por: Xia, Shuai, et al.
Publicado: (2014)

A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike
por: Xia, Shuai, et al.
Publicado: (2019)

SARS-CoV-2 Omicron subvariant BA.2.86: limited potential for global spread
por: Wang, Xinling, et al.
Publicado: (2023)

Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV
por: Zheng, Ming, et al.
Publicado: (2020)

No crossreactivity of anti-SARS-CoV-2 spike protein antibodies with Syncytin-1
por: Prasad, Mukul, et al.
Publicado: (2021)

Letter to the Editor in response to the article: “Nebulization: a potential source of SARS-CoV-2 transmission”
por: Anzueto, A., et al.
Publicado: (2021)

BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants
por: Liu, Yang, et al.
Publicado: (2021)

Retraction of articles
Publicado: (2012)

Retraction of articles
Publicado: (2011)

Retraction of articles
Publicado: (2010)

Retraction of articles
Publicado: (2012)

Retraction of articles
Publicado: (2011)

Articles retraction
Publicado: (2018)

Captain Sumner's Recent Article
por: Knapp, H. H. E.
Publicado: (1908)

SARS-CoV-2 spike E484K mutation reduces antibody neutralisation
por: Jangra, Sonia, et al.
Publicado: (2021)

Evolving spike mutations in SARS-CoV-2 Omicron variants facilitate evasion from breakthrough infection-acquired antibodies
por: Chen, Shiqi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1mnc27uj57g6c01pbfdke70bna